AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

The Lafayette Area Parkinson's Support, known as LeAPS, is a new nonprofit that will be offered to those impacted by ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

THOSE afflicted with Parkinson’s disease (PD) must contend with tremors, stiffness, and uncontrollable movements in their body as a result of the deterioration of their nervous system. Proper care is ...

Initiation of Phase 1b Study of GT-02287 in Parkinson's patients expected by end of 2024 BETHESDA, Md., Nov. 14, 2024 (GLOBE ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Parkinson's coach at the Step Up for Parkinson's Therapy Clinic; Yaser Teebi, clinical psychologist and gerontologist specialising in Geriatrics and Gerontology and PhD Dementia candidate at the ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...